GemPharmatech branches out with preclinical research sites in U.S.

By The Science Advisory Board staff writers

February 22, 2021 -- China's GemPharmatech, a provider of laboratory animals, has launched new research sites in the U.S. that will house 6,000 research models.

The Nanjing, China-based company said that it has a large collection of about 15,000 models, including conditional knockout, knockout mice, and immune-deficient mice, generated using gene editing technologies. The new facilities are based in Massachusetts and California.

The company hopes to provide tools and services faster and closer to its research and development customers, including large pharmaceutical and biotechnology companies, contract research organizations (CROs), universities, and research institutions in the U.S.

New mouse-adapted model helps accelerate COVID-19 vaccines, therapies
A new mouse-adapted SARS-CoV-2 model developed with engineered virus can help accelerate vaccine and therapeutic candidates to clinical trials. The results...

Copyright © 2021 scienceboard.net


Register below for our weekly Letter from the Editor to receive the latest Science news and insights.
Email
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter